JP6466397B2 - 抗原特異的ｂ細胞の同定及び単離ならびに所望の抗原に対する抗体作製のプロトコール - Google Patents

抗原特異的ｂ細胞の同定及び単離ならびに所望の抗原に対する抗体作製のプロトコール Download PDF

Info

Publication number
JP6466397B2
JP6466397B2 JP2016502597A JP2016502597A JP6466397B2 JP 6466397 B2 JP6466397 B2 JP 6466397B2 JP 2016502597 A JP2016502597 A JP 2016502597A JP 2016502597 A JP2016502597 A JP 2016502597A JP 6466397 B2 JP6466397 B2 JP 6466397B2
Authority
JP
Japan
Prior art keywords
antigen
cells
specific
cell
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016502597A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512044A (ja
JP2016512044A5 (cg-RX-API-DMAC10.html
Inventor
アリスン，ダニエル・エス
デュツァー，ベンジャミン・エイチ
ガルシア−マルティネス，レオン・エフ
アンダーソン，ケイティ
オーハラ，イーサン・ダブリュー
ラザム，ジョン・エイ
ビルグレン，イェンス
ジェンセン，アン・エリザベス・カルヴァロ
Original Assignee
アルダー・バイオファーマシューティカルズ・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルダー・バイオファーマシューティカルズ・インコーポレーテッド filed Critical アルダー・バイオファーマシューティカルズ・インコーポレーテッド
Publication of JP2016512044A publication Critical patent/JP2016512044A/ja
Publication of JP2016512044A5 publication Critical patent/JP2016512044A5/ja
Application granted granted Critical
Publication of JP6466397B2 publication Critical patent/JP6466397B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
JP2016502597A 2013-03-15 2014-03-18 抗原特異的ｂ細胞の同定及び単離ならびに所望の抗原に対する抗体作製のプロトコール Expired - Fee Related JP6466397B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361791755P 2013-03-15 2013-03-15
US61/791,755 2013-03-15
PCT/US2014/030994 WO2014146074A2 (en) 2013-03-15 2014-03-18 Protocol for identifying and isolating antigen-specific b cells and producing antibodies to desired antigens

Publications (3)

Publication Number Publication Date
JP2016512044A JP2016512044A (ja) 2016-04-25
JP2016512044A5 JP2016512044A5 (cg-RX-API-DMAC10.html) 2017-04-20
JP6466397B2 true JP6466397B2 (ja) 2019-02-06

Family

ID=51538609

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016502597A Expired - Fee Related JP6466397B2 (ja) 2013-03-15 2014-03-18 抗原特異的ｂ細胞の同定及び単離ならびに所望の抗原に対する抗体作製のプロトコール

Country Status (8)

Country Link
US (2) US20140287952A1 (cg-RX-API-DMAC10.html)
EP (1) EP2972330A4 (cg-RX-API-DMAC10.html)
JP (1) JP6466397B2 (cg-RX-API-DMAC10.html)
KR (1) KR20150140679A (cg-RX-API-DMAC10.html)
AU (1) AU2014232225B2 (cg-RX-API-DMAC10.html)
CA (1) CA2907570A1 (cg-RX-API-DMAC10.html)
IL (1) IL241433B (cg-RX-API-DMAC10.html)
WO (1) WO2014146074A2 (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
GB201316644D0 (en) 2013-09-19 2013-11-06 Kymab Ltd Expression vector production & High-Throughput cell screening
MX378344B (es) 2014-03-21 2025-03-10 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
EP3233916A4 (en) 2014-12-19 2018-06-06 Alder Biopharmaceuticals, Inc. Humanized anti-acth antibodies and use thereof
EP3271393A4 (en) * 2015-03-18 2018-10-31 Epitomics, Inc. High throughput monoclonal antibody generation by b cell panning and proliferation
US20190056398A1 (en) * 2016-02-26 2019-02-21 Sri International Identification and isolation of antibodies from white blood cells
SG10202109691UA (en) 2016-04-15 2021-10-28 Alder Biopharmaceuticals Inc Anti-pacap antibodies and uses thereof
SMT202600087T1 (it) 2016-09-23 2026-03-09 Teva Pharmaceuticals Int Gmbh Trattamento dell’emicrania refrattaria
WO2018102612A1 (en) 2016-12-02 2018-06-07 Juno Therapeutics, Inc. Engineered b cells and related compositions and methods
CN108700576B (zh) * 2017-01-20 2021-07-02 深圳市新产业生物医学工程股份有限公司 制备抗体对的方法、试剂盒及试剂盒的应用和制备抗体对的系统
US11125757B2 (en) * 2017-05-26 2021-09-21 Emory University Methods of culturing and characterizing antibody secreting cells
CN107058235B (zh) * 2017-06-05 2020-08-11 深圳大学 一种b细胞筛选方法及其在单克隆抗体制备中的应用
US20220034902A1 (en) * 2018-12-11 2022-02-03 Merck Sharp & Dohme Corp. Method for identifying high affinity monoclonal antibody heavy and light chain pairs from high throughput screens of b-cell and hybridoma libraries
WO2020242856A1 (en) * 2019-05-31 2020-12-03 The Penn State Research Foundation Specific selection of immune cells using versatile display scaffolds
JP2023519782A (ja) * 2020-01-17 2023-05-15 ジャンプコード ゲノミクス，インク． 標的化された配列決定の方法
CN114441752B (zh) * 2020-11-03 2024-11-26 中国科学院苏州纳米技术与纳米仿生研究所 一种筛选方法
WO2022170074A1 (en) * 2021-02-05 2022-08-11 Amgen Inc. Enhanced hybridoma generation
CN115166241B (zh) * 2022-08-22 2023-03-24 广东忠信生物科技有限公司 一种同时筛选记忆b细胞和浆细胞的高效筛选技术及应用
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2026120069A1 (en) 2024-12-05 2026-06-11 H. Lundbeck A/S Humanized anti-pacap antibody and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990000625A1 (en) * 1988-07-14 1990-01-25 Monoclonetics International, Inc. Pre-screening for depletion and enrichment of specific b-cells
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
DE69126281T2 (de) * 1990-11-26 1997-10-16 Akzo Nobel Nv Verfahren zur Herstellung von Antikörpern
US5256542A (en) * 1992-03-09 1993-10-26 Tanox Biosystems, Inc. Selecting low frequency antigen-specific single B lymphocytes with correction for background noise
US5213960A (en) * 1992-03-09 1993-05-25 Tanox Biosystems, Inc. Methods for selecting low frequency antigen-specific single B lymphocytes
US20050287607A1 (en) * 2004-01-07 2005-12-29 Diamond Betty A Methods and compositions for identification of antigen-specific B cell populations
US20060051348A1 (en) * 2004-09-09 2006-03-09 Jorn Gorlach Method of producing a plurality of isolated antibodies to a plurality of cognate antigens
JP2008517914A (ja) * 2004-10-22 2008-05-29 ジェネンコー・インターナショナル・インク ヒトの抗体の分離方法
WO2007046757A1 (en) * 2005-10-17 2007-04-26 Gambro Lundia Ab Extracorporeal blood cleaning
EP2021463B1 (en) * 2006-05-19 2016-11-23 Alder Biopharmaceuticals, Inc. Culture method for obtaining a clonal population of antigen-specific b cells
WO2008073166A2 (en) * 2006-08-23 2008-06-19 Xcellerex, Inc. Multi-variant cell indication technique
NZ578851A (en) * 2007-03-01 2011-09-30 Symphogen As Method for cloning cognate antibodies
EP2238167B1 (en) * 2007-12-27 2015-04-22 Abbott Laboratories Anti-t. cruzi antibodies and methods of use
SI2400298T1 (sl) 2010-05-28 2013-11-29 F. Hoffmann-La Roche Ag Postopek kultivacije posamezne B-celice in izdelava specifičnih protiteles
KR20140043720A (ko) * 2011-03-01 2014-04-10 노보 노르디스크 에이/에스 길항성 ｄｒ3 리간드
WO2013076139A1 (en) * 2011-11-23 2013-05-30 F. Hoffmann-La Roche Ag Cd40l expressing mammalian cells and their use
WO2013130462A1 (en) * 2012-02-29 2013-09-06 Medimmune, Llc Antibody production methods

Also Published As

Publication number Publication date
KR20150140679A (ko) 2015-12-16
AU2014232225A1 (en) 2015-09-03
IL241433A0 (en) 2015-11-30
EP2972330A2 (en) 2016-01-20
US20140287952A1 (en) 2014-09-25
EP2972330A4 (en) 2016-10-26
WO2014146074A3 (en) 2014-11-06
IL241433B (en) 2019-12-31
AU2014232225B2 (en) 2020-03-19
JP2016512044A (ja) 2016-04-25
CA2907570A1 (en) 2014-09-18
US20160033504A1 (en) 2016-02-04
WO2014146074A2 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
AU2014232225B2 (en) Protocol for identifying and isolating antigen-specific B cells and producing antibodies to desired antigens
AU2007307324B2 (en) Culture method for obtaining a clonal population of antigen-specific B cells
US20100034807A1 (en) Methods and compositions for discovery of target-specific antibodies using antibody repertoire array (ara)
US10934524B2 (en) High throughput monoclonal antibody generation by B cell panning and proliferation
CN120623348A (zh) 一种抗人cd3兔重组单克隆抗体及其制备方法与应用
CN115386006A (zh) 抗gprc5d抗体、其制备方法与用途
CN119409823B (zh) 靶向食蟹猴bdca-2的单克隆抗体及其应用
Zhai et al. Monoclonal Antibody Development Technology for Important Human Diseases
CN121005774A (zh) 小鼠肝炎病毒抗体及其应用
CN119752789A (zh) 从猴外周血中分离单个抗原特异性b淋巴细胞的方法
CN121159693A (zh) 一种结合人cd8的单克隆抗体及其制备方法与应用
HK1127372B (en) Culture method for obtaining a clonal population of antigen-specific b cells
HK1127372A (en) Culture method for obtaining a clonal population of antigen-specific b cells
CN120623347A (zh) 一种结合人cd4的单克隆抗体及其制备方法与应用
CN119431580A (zh) 一种抗人tigit单克隆抗体及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170315

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180423

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180723

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181023

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181211

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190109

R150 Certificate of patent or registration of utility model

Ref document number: 6466397

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees